Inogen reports recurring developments as a respiratory medical technology company serving homecare patients with chronic respiratory conditions. Its updates focus on financial results and outlook, portable oxygen concentrators, Simeox airway clearance, stationary oxygen concentrators, and Aurora CPAP masks for obstructive sleep apnea.
Company news also covers product introductions, clinical evidence and reimbursement work, international market activity, commercial partnerships, leadership and board changes, inducement equity awards, share repurchase actions, and investor conference participation.
Inogen, Inc. (NASDAQ: INGN), a leader in respiratory health technologies, will present at the 41st Annual William Blair Virtual Growth Stock Conference on June 3rd, 2021, at 4:00 p.m. CDT. CEO Nabil Shabshab and CFO Alison Bauerlein will lead the presentation, which can be accessed via the company's Investor Relations page. This presentation highlights Inogen's commitment to innovation in portable oxygen concentrators, enhancing care options for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) reported Q1 2021 revenue of $86.9 million, a 1.8% decline from Q1 2020, largely due to COVID-19 impacts. Domestic business-to-business revenue rose 11.6% to $30.7 million, while rental revenue surged 84.2% to $9.9 million. As of March 31, 2021, cash and equivalents totaled $233.2 million, with no debt. Operating loss was $2.1 million, and net loss was $0.7 million. The company refrained from providing full-year guidance for 2021 due to pandemic uncertainties, while anticipating increased operational expenses as it invests in growth initiatives.
Inogen, a medical technology company focused on respiratory products, will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 1:30 PM PT/4:30 PM ET, with a replay available until May 18, 2021. Investors can listen live via phone or through Inogen's Investor Relations website. The company specializes in portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) announced the appointment of George Parr as Executive Vice President and Chief Commercial Officer, effective April 12, 2021. This follows the planned departure of Byron Myers and Arron Retterer, effective June 4, 2021. Inogen expects first-quarter 2021 revenue to range from $84.0 million to $87.0 million, based on preliminary estimates. Parr brings over 25 years of experience in the medical technology sector, which the company hopes will enhance growth and patient access to its products. The leadership changes aim to strengthen Inogen’s market position.
Inogen, a medical technology company known for innovative respiratory products, will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021. President and CEO Nabil Shabshab and CFO Alison Bauerlein will host the presentation at 10:15 a.m. ET. Interested parties can access the webcast on Inogen's Investor Relations website, with a replay available for 90 days following the event. Inogen specializes in portable oxygen concentrators designed for long-term supplemental oxygen therapy in homecare settings.
Inogen, Inc. (NASDAQ: INGN), a medical technology company, announced its participation in the KeyBanc Life Sciences & MedTech Investor Forum. The presentation is scheduled for March 23, 2021, at 3:30 p.m. ET, featuring President and CEO Nabil Shabshab, and CFO Alison Bauerlein. Interested individuals can access the webcast on Inogen's Investor Relations page. The company emphasizes transparency by utilizing its website to disclose non-public material information in compliance with Regulation FD. Inogen develops innovative portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, a medical technology company, reported Q4 2020 revenue of $74 million, down 6.3% year-over-year, primarily impacted by COVID-19. Domestic B2B sales rose 17.9% to $24.2 million, while rental revenue surged 71.7% to $9.4 million. The company incurred a net loss of $5.1 million and had cash reserves of $231.2 million with no debt. For 2021, Inogen refrained from providing financial guidance due to market uncertainties but anticipates improvements in domestic sales and rental revenue despite expected declines in international and direct-to-consumer sales.
Inogen, Inc. (NASDAQ: INGN) announced the appointment of Kristen Miranda to its Board of Directors, effective March 1, 2021, filling the vacancy left by Scott Beardsley’s resignation. Miranda brings extensive healthcare experience, having served as Aetna’s West Region President since 2017. Her addition aims to enhance payor acceptance of Inogen’s products. CEO Nabil Shabshab emphasized her healthcare background as a key asset for expanding patient access and enhancing shareholder value. The company continues to focus on innovative respiratory solutions for homecare settings.
Inogen, Inc. (NASDAQ: INGN) announced its participation in the 10th Annual SVB Leerink Healthcare Conference, scheduled for February 25, 2021. CEO Nabil Shabshab and CFO Alison Bauerlein will present at 2:20 p.m. ET. The presentation can be accessed via the Investor Relations page on Inogen's website, with a replay available for 90 days post-event. Inogen focuses on developing innovative respiratory products, particularly portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, Inc. (Nasdaq: INGN) will release its fourth quarter and year-end 2020 financial results on February 24, 2021, after market close. Following the release, a conference call will be held at 1:30 PM PT/4:30 PM ET, where investors can participate by calling (877) 841-3961 domestically or (201) 689-8589 internationally. A replay will be available from February 24, 2021, at 3:30 PM PT until March 10, 2021. Inogen specializes in respiratory products, particularly portable oxygen concentrators for patients with chronic respiratory conditions.